- Home
- TECX vs MREO Comparison
TECX vs MREO Comparison
Compare TECX & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- MREO
- Stock Information
- Founded
- TECX 2019
- MREO 2015
- Country
- TECX United States
- MREO United Kingdom
- Employees
- TECX N/A
- MREO N/A
- Industry
- TECX
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- MREO Health Care
- Exchange
- TECX Nasdaq
- MREO Nasdaq
- Market Cap
- TECX 387.1M
- MREO 311.8M
- IPO Year
- TECX 2018
- MREO N/A
- Fundamental
- Price
- TECX $18.92
- MREO $1.84
- Analyst Decision
- TECX Buy
- MREO Strong Buy
- Analyst Count
- TECX 6
- MREO 5
- Target Price
- TECX $79.17
- MREO $7.40
- AVG Volume (30 Days)
- TECX 682.4K
- MREO 1.6M
- Earning Date
- TECX 11-06-2025
- MREO 11-10-2025
- Dividend Yield
- TECX N/A
- MREO N/A
- EPS Growth
- TECX N/A
- MREO N/A
- EPS
- TECX N/A
- MREO N/A
- Revenue
- TECX N/A
- MREO $500,000.00
- Revenue This Year
- TECX N/A
- MREO N/A
- Revenue Next Year
- TECX N/A
- MREO $72.16
- P/E Ratio
- TECX N/A
- MREO N/A
- Revenue Growth
- TECX N/A
- MREO N/A
- 52 Week Low
- TECX $13.70
- MREO $1.47
- 52 Week High
- TECX $61.07
- MREO $4.29
- Technical
- Relative Strength Index (RSI)
- TECX 55.49
- MREO 45.03
- Support Level
- TECX $18.49
- MREO $1.65
- Resistance Level
- TECX $20.39
- MREO $1.93
- Average True Range (ATR)
- TECX 2.22
- MREO 0.12
- MACD
- TECX 0.14
- MREO -0.02
- Stochastic Oscillator
- TECX 31.09
- MREO 36.00
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).